Pharming Group N.V., a biopharmaceutical company develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases globally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE) Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
It also develops Joenja, an oral small molecule PI3K? inhibitor. It has a development collaboration and license agreement with Novartis. Incorporated in 1988, Pharming is headquartered in Leiden, the Netherlands.
Pharming Group N.V. is a biopharmaceutical company that develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases globally. Its lead product is RUCONEST, a recombinant C1 esterase inhibitor used to treat acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE). The company also offers Joenja (leniolisib), an oral small molecule PI3Kδ inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. Additionally, Pharming has a development collaboration and license agreement with Novartis.
Where is Pharming Group N.V. (PHAR) listed and in what currency?
Pharming Group N.V. is listed on the Nasdaq Global Market (NasdaqGM) under the ticker symbol PHAR. Its securities trade in US dollars (USD). The company is headquartered in Leiden, the Netherlands, and its stock is accessible to investors in the US region.
What sector and industry does Pharming Group N.V. (PHAR) belong to?
Pharming Group N.V. operates in the Healthcare sector and specifically within the Biotechnology industry. As a biopharmaceutical company, it focuses on developing and commercializing therapies for rare diseases, leveraging recombinant protein technology and precision medicine approaches.
Where is Pharming Group N.V. (PHAR) headquartered and what markets does it serve?
Pharming Group N.V. is headquartered in Leiden, the Netherlands. The company serves global markets, with its products targeting patients with rare diseases worldwide. Its lead product, RUCONEST, is used for hereditary angioedema, and Joenja addresses activated phosphoinositide 3-kinase delta syndrome, both of which are distributed internationally.
What are the main products of Pharming Group N.V. (PHAR)?
Pharming Group N.V.'s main products include RUCONEST, a recombinant C1 esterase inhibitor for treating acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE), and Joenja (leniolisib), an oral small molecule PI3Kδ inhibitor for treating activated phosphoinositide 3-kinase delta syndrome. The company also has a development collaboration and license agreement with Novartis, though specific details of this collaboration are not provided.
Pharming reported second quarter and first half 2026 financial results and revised year-end guidance. Second quarter 2026 total revenues decreased 3% to US$90.2 million.